9 terminated. 9 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Terminated 9 |
| Phase 1 | 4 | Terminated 4 |
Follow copanlisib: new trials by email Literature Review of copanlisib trials Research Report on copanlisib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations Copanlisib, fulvestrant - Endometrial Cancer, Ovarian Cancer | Phase 2 | Terminated | M.D. Anderson Cancer Center | 7 | 2022-09-27 | 2026-01-09 |
| Study of Copanlisib and Ketogenic Diet Copanlisib, Ketogenic Diet - Follicular Lymphoma, Endometrial Cancer | Phase 2 | Terminated | Columbia University | 1 | 2022-02-10 | 2025-03-04 |
| Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer Copanlisib, Pertuzumab, Trastuzumab - Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 2 | 2021-05-20 | 2025-10-01 |
| Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma Copanlisib - Diffuse Large B-cell Lymphoma | Phase 2 | Terminated | Fondazione Italiana Linfomi - ETS | 37 | 2020-08-18 | 2025-08-08 |
| Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Copanlisib, Rituximab, Bendamustine - Lymphoid Leukemia, Non-Hodgkin's Lymphoma | Phase 2 | Terminated | University of Washington | 1 | 2020-01-31 | 2022-04-11 |
| Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients Copanlisib (BAY806946) - Relapsed or Refractory Solid Tumors or Lymphoma in Children, Neuroblastoma | Phase 1 / Phase 2 | Terminated | Bayer | 31 | 2018-04-30 | 2023-12-04 |
| Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss Copanlisib, Cetuximab - Carcinoma, Squamous Cell of Head and Neck | Phase 1 / Phase 2 | Terminated | UNICANCER | 11 | 2016-06-01 | 2021-03-29 |
| Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma MK-3475, Copanlisib - Lymphoma, T-Cell, Peripheral | Phase 1 / Phase 2 | Terminated | Fox Chase Cancer Center | 17 | 2016-01-05 | 2022-07-08 |
| Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL) Copanlisib (BAY80-6946) - Lymphoma, Mantle-Cell | Phase 2 | Terminated | Bayer | 4 | 2015-08-24 | 2017-10-02 |
Endometrial Neoplasms (2) · Breast Neoplasms (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Lymphoid (1) · Lymphoma (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell, Peripheral (1) · Neuroblastoma (1) · Osteosarcoma (1) · Ovarian Neoplasms (1) · Recurrence (1) · Rhabdomyosarcoma (1)
Bayer (2) · Columbia University (1) · Fondazione Italiana Linfomi - ETS (1) · Fox Chase Cancer Center (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · UNICANCER (1) · University of Washington (1)
United States (7) · France (1) · Italy (1)
Henry Fung, MD (1) · Jennifer E. Amengual, MD (1) · Ryan Lynch (1) · Senthilkumar Damodaran (1) · Timothy Yap, MD (1) · Umberto Vitolo (1)
2015 (1), 2017 (1), UM1CA186688 (1)